Citation Impact
Citing Papers
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
2018
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
2009
A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia
2018 StandoutNobel
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
2012
Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA
2011 StandoutScience
Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung Cancer
2011
Evolution of the Cancer Stem Cell Model
2014 Standout
5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies
2014
Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice
2014
Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome
2010
The molecular hallmarks of epigenetic control
2016 Standout
Functions of DNA methylation: islands, start sites, gene bodies and beyond
2012 Standout
Post-remission therapy for acute myeloid leukemia
2014
DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes
2008
Influence of Metabolism on Epigenetics and Disease
2013 StandoutNobel
Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells
2012
Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty
2012 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
2011 StandoutNature
Epigenetics and the environment: emerging patterns and implications
2012 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
New treatment for acute myelogenous leukemia
2014
Acute Myeloid Leukemia in the Elderly
2008
The emerging role of lncRNAs in cancer
2015 Standout
Gene Reactivation by 5-Aza-2′-Deoxycytidine–Induced Demethylation Requires SRCAP–Mediated H2A.Z Insertion to Establish Nucleosome Depleted Regions
2012
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
2018 StandoutNobel
Cancer stem cells revisited
2017 Standout
DNA methylation: roles in mammalian development
2013 Standout
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Refractory anemia with ring sideroblasts
2013
Advances in DNA methylation: 5-hydroxymethylcytosine revisited
2011
PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia
2016
The hypoxic tumor microenvironment: A driving force for breast cancer progression
2015 StandoutNobel
Exploring in vitro expression and immune potency in mice using mRNA encoding the Plasmodium falciparum malaria antigen, CelTOS
2022 StandoutNobel
Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors
2012
Targeting apoptosis in cancer therapy
2020 Standout
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
2013 Standout
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
TET enzymes, TDG and the dynamics of DNA demethylation
2013 StandoutNature
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas
2008
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
2013
Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study
2020
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
2013
Epigenetic modifications as therapeutic targets
2010
Leukaemogenesis: more than mutant genes
2009
The Epidemiology of Myelodysplastic Syndromes
2010
Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia
2008
Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson
2013
Recent developments in epigenetics of acute and chronic kidney diseases
2015
Therapy with azanucleosides for myelodysplastic syndromes
2010
Epigenetic modifications and human disease
2010 Standout
A decade of exploring the cancer epigenome — biological and translational implications
2011 Standout
The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome
2012
The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells
2012
Chronic Kidney Disease
2016 Standout
The cancer genome
2009 StandoutNature
Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
2017 StandoutNature
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
2011
Polyamine metabolism and function
1982 Standout
Myelodysplastic Syndromes Clinical Practice Guidelines in Oncology
2006
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
2014
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
2010
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
2014
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
2010
CYTOMEGALOVIRUS AND KAPOSI'S SARCOMA IN YOUNG HOMOSEXUAL MEN
1982
Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's Sarcoma
1994 StandoutScience
Recent developments in myelodysplastic syndromes
2014
Acute Myeloid Leukemia
2015 Standout
Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays
2014 Standout
Peptidic degron for IMiD-induced degradation of heterologous proteins
2019 StandoutNobel
New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndrome
2011
Neurological complications of acquired immune deficiency syndrome: Analysis of 50 patients
1983 Standout
Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings
2016
Results of phase 2 randomized study of low‐dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia
2014
Rapid Diagnosis of Cytomegaloviral Pneumonia by Tissue Immunofluorescence with a Murine Monoclonal Antibody
1985 StandoutNobel
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
2017 Standout
The emerging role of immune checkpoint based approaches in AML and MDS
2017 StandoutNobel
Loss of TET proteins in regulatory T cells promotes abnormal proliferation, Foxp3 destabilization and IL-17 expression
2019 StandoutNobel
Combination therapy in combating cancer
2017 Standout
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
Cancer treatment and survivorship statistics, 2016
2016 Standout
Formation and interconversion of putrescine and spermidine in mammalian cells
1981
Cancer treatment and survivorship statistics, 2019
2019 Standout
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
2015 Standout
Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
2009 Standout
Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure
2016
Characterization of DNA Methylation in Circulating Tumor Cells
2015
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
2018
Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
2010
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Hypomethylation and up-regulation ofPD-1in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
2015
Applicability of a “Pick a Winner” trial design to acute myeloid leukemia
2011
Works of Jay T. Backstrom being referenced
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
2009
Aberrant regulation of ornithine decarboxylase by serum, putrescine, and spermidine in cytomegalovirus-transformed human cells.
1979
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
2009 Standout
Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes
2010
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)
2014
Prolonged survival with improved tolerability in higher‐risk myelodysplastic syndromes: azacitidine compared with low dose ara‐C
2010
Results of the Initial Treatment Phase of a Study of Three Alternative Dosing Schedules of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS).
2007
The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)
2008
Further Analysis of Trials With Azacitidine in Patients With Myelodysplastic Syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
2006
Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.
2007
Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission
2008
Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
2009
A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma
2007